Ŀ¼ CsZ~LQ=DB
ͬ¼ÃÒ½¿Æ´óѧ1999ÄêÄÚ¿ÆѧÊÔÌâ .psb#4
ͬ¼ÃÒ½¿Æ´óѧ2000ÄêÄÚ¿ÆѧÊÔÌâ %"WENa/t
ÄϾ©Ò½¿Æ´ó99ÄêÉñ¾²¡Ñ§ *yBVZD|?H
ºÓ±±Ò½¿Æ´ó2001ÄêÉñ¾²¡Ñ§ÊÔÌâ PaCCUF
2005ÄêÖÐɽҽ´ó²¡ÉúÊÔÌâ |A&;m}(Mt
ÄÏ·½Ò½¿Æ´óѧ2005ÃâÒßÌâ DU^.5f
2005ÄêкͲ©Ê¿ÃâÒßÊÔÌ⣨רҵ»ù´¡£© ~$J;yo~
2005Äêͬ¼Ã²©Ê¿ÈëѧÕï¶ÏÌâ J"a
w 1
2005É϶þÒ½²©Ê¿·Ö×ÓÉúÎïѧ£¨×¨Òµ»ù´¡£© )re<NE&M
2005ÄêÉ϶þÒ½²©Ê¿Éú»¯¿¼Ìâ P< OH{l
ÄÏ·½Ò½¿Æ´óѧ2005ϸ°ûÉúβ©ÊÔÌâ -1Q24jrO-
2005Ä긴µ©´óѧ·ÅÁÆ¿¼²©ÊÔÌâ Ema[M5$R
ͬ¼ÃÒ½¿ÆÔºÀúÄêÉñ¾½âÆÊѧÊÔÌâ T}fo
2004ÄêÊ×Ò½Éñ¾½âÆÊÌâ Ci`o;KVj
µÚËľüÒ½´óѧÀúÄêÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ j_<qnBe
Q
N@d~gE&^
¾ßÌå¼ûÏÂ: DzVCEhf
<^YvgQ,m
ͬ¼ÃÒ½¿Æ´óѧ1999ÄêÄÚ¿ÆѧÊÔÌâ 7_\
G|Zd
Ò»¡¢ Ãû´Ê½âÊÍ£º1¡¢¾üÍžú²¡Àú¡¢¸ßѪѹÄÔ²¡3¡¢Î¸ÃÚËØÁö4¡¢Õù½øÐÔÉöÑ×5¡¢PhȾɫÌå6¡¢Grares²¡ WARiw[
¶þ¡¢Ìî¿Õ£º1¡¢ÂýÐÔºôÎüË¥½ßIÐ͵ÄѪÆø·ÖÎöÌص㣨1£© £¬IIÐ͵ÄѪÆø·ÖÎöÌص㣨2£© ¡£ 2¡¢ÐÄÔà´«µ¼ÒõÖÍ°üÀ¨£¨1£© £¨2£© £¨3£© £¨4£© ¡£ 3¡¢Ä¿Ç°ÒÖÖÆθËá·ÖÃÚ×îÇ¿µÄÒ»ÀàÒ©ÊÇ£¨1£© 4¡¢½áºËÐÔ¸¹Ä¤Ñ××î³£¼ûµÄ²¢·¢Ö¢ÊÇ£¨1£© 5¡¢¼±ÐÔÉö¹¦ÄÜË¥½ßÁÙ´²Ò»°ã·ÖΪ£¨1£© £¨2£© £¨3£© ÈýÆÚ¡£ 6¡¢ÓлúÁ×Å©Ò©Öж¾µÄ»úÀíÖ÷ÒªÊÇÒÖÖÆÁË£¨1£© £»Ò»Ñõ»¯Ì¼Öж¾Ê±£¬»úÌå¶ÔȱÑõ×îÃô¸ÐµÄÆ÷¹ÙÊÇ£¨2£© £¨3£© ¡£ 7¡¢¸ù¾Ý²¡ÒòºÍ·¢²¡»úÖÆ£¬½«Æ¶Ñª·ÖΪ£¨1£© £¨2£© £¨3£© ÈýÀà¡£ 8¡¢¼±ÐÔ°×Ѫ²¡µÄMIC·ÖÐÍÊÇÖ¸£¨1£© £¨2£© £¨3£© µÄ·ÖÐÍ¡£9¡¢¿Ú·þ½µÌÇÒ©Îï·ÖΪ£¨1£© ºÍ£¨2£© Á½Àà¡£ 10¡¢Ð¡¼ÁÁ¿µØÈûÃ×ËÉÒÖÖÆÊÔÑéÖ÷ÒªÓÃÓÚ£¨1£© Ó루2£© µÄ¼ø±ðÕï¶Ï£»´ó¼ÁÁ¿µØÈûÃ×ËÉÒÖÖÆÊÔÑéÖ÷ÒªÓÃÓÚ£¨3£© ºÍ£¨4£© µÄ¼ø±ð¡£ iT'doF
Èý¡¢ ¼ò´ðÌ⣺1¡¢¼òÊöÂýÐÔÖ§Æø¹ÜÑ×µÄÕï¶Ï±ê×¼¡£2¡¢ºÎΪǰ¸ººÉ¡¢ºó¸ººÉ£¿3¡¢Ô·¢ÐԸΰ©×ÛºÏÕ÷ÓÐÄÄЩ±íÏÖ£¿ ?lC>E[
,p|Q/M^
ͬ¼ÃÒ½¿Æ´óѧ2000ÄêÄÚ¿ÆѧÊÔÌâ i:s=
Ò»¡¢ Ãû´Ê½âÊÍ£º1¡¢ÕÅÁ¦ÐÔÆøÐØ2¡¢ÐÄÁ¦Ë¥½ß3¡¢Grey-TurnerÕ÷4¡¢IgAÉö²¡5¡¢AureСÌå6¡¢Ï¯ºº×ÛºÏÕ÷
_=HaE&
¶þ¡¢Ìî¿Õ£º1¡¢ÁÙ´²Õï¶Ï·Î½áºËʱ£¬Ó¦°üÀ¨ ¡¢ ¡¢ ¡¢ Ëĸö²¿·Ö¡£ 2¡¢ÑóµØ»ÆÀàÒ©ÎïËØÐÔ·´Ó¦µÄÁÙ´²±íÏÖÓÐ ¡¢ ¡¢ ¡£ 3¡¢¸ÎÓ²»¯ÉÏÏû»¯µÀ³öѪµÄ²¡ÒòÓÐ ¡¢ ¡¢ ¡£ 4¡¢ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ£¨DIC£©µÄÁÙ´²±íÏÖÓÐ ¡¢ ¡¢ ¡¢ ¡£5¡¢ÈÜѪÐÔƶѪʱºìϸ°û´ú³¥ÐÔÔöÉúµÄ±íÏÖÓÐ ¡¢ ¡¢ ¡£ 6¡¢ËáÈÜѪÊÔÑ飨HamÊÔÑ飩ÑôÐÔ¿ÉÒÔÕï¶Ï £¬ÓÃÓÚÕï¶Ï²¢¼ø±ðѪÓѲ¡ÀàÐ͵ÄʵÑéÊÒ¼ì²éÊÇ ¡£ 7¡¢ÉÙÄòÊÇÖ¸ £¬ÎÞÄòÊÇÖ¸ 8¡¢Éö×ÛºÏÕ÷µÄ²¢·¢Ö¢ÓÐ ¡¢ ¡¢ ¡¢ ¡£ 9¡¢¼±¿¯ÐÔÉöÑ׵IJ¡ÀíÑÕ÷Ϊ ¡¢ÔçÆÚΪ £¬ºóÆÚΪ ¡£ 10¡¢¼±ÐÔÓлúÁ×Öж¾Ö÷ÒªÁÙ´²±íÏÖÓÐ ¡¢ ¡¢ Èý¸ö·½Ãæ¡£ 11¡¢¿¹¼××´ÏÙÒ©Îï³£ÓõÄÊÇ À࣬Æä×÷ÓûúÖÆÊÇ ºÍ ¡£ 12¡¢ÌÇÄò²¡ÍªÖ¢ËáÖж¾²¹¼îÖ¸Õ÷Ϊ »ò ¡£ 13¡¢ÄâÅųýÊȸõϸ°ûÁöÒýÆðµÄ¸ßѪѹ£¬Ó¦×ö ʵÑéÊÒ¼ì²é°ïÖúÕï¶Ï¡£ 3Q,&D'];[
Èý¡¢¼ò´ðÌ⣺1¡¢¼òÊö½áºËÐÔÐØĤÑ×ÐØË®Ìص㡣 2¡¢¼òÊöÕó·¢ÐÔÊÒÉÏÐÔÐĶ¯¹ýËÙµÄÖÎÁÆÔÔò¡£ 3¡¢¼òÊö¸ÎÐÔÄÔ²¡µÄÖ÷ÒªÕï¶ÏÒÀ¾Ý¡£
,C,nNaW
f&<+45JI
ÄϾ©Ò½¿Æ´ó99ÄêÉñ¾²¡Ñ§ #B\s'j[A"
1.¡¢ÊÔÊö²¡¶¾ÐÔÄÔÑ׵ıíÏÖ£¿ ¶þ¡¢ÊÔÊöСÄÔ²¡±äµÄÁÙ´²±íÏÖ£¿ Èý¡¢ÊÔÊöÄÔðÞµÄÁÙ´²±íÏÖ£¿ 3¡¢Ãû´Ê½âÊÍ 1.¸Ð¾õÐÔʧÓï 2¡¢±È¸¥×ÛºÏÕ÷ 8dR `T}
y i$+rPF1
ºÓ±±Ò½¿Æ´ó2001ÄêÉñ¾²¡Ñ§ÊÔÌâ vn}m-U XA*
Ò».ÖÜΧÉñ¾¼²²¡»ù±¾²¡Àí±ä»¯Óм¸ÖÖ?²¢¼ÓÒÔ˵Ã÷ ¶þ.¼òÊöÖëÍøĤÏÂÇ»³öѪµÄÖ¢×´,ÌåÕ÷ºÍÖÎÁÆÔÔò,²¢¾Ù³öÈýÖÖ³£¼û²¡Òò? Èý¡¢ÖØÖ¢¼¡ÎÞÁ¦·¢²¡ÔÀí?ºÎν¼¡ÎÞÁ¦Î£Ïó¼°µ¨¼îÄÜΣÏó?Èç·¢ÉúÉÏÊöÁ½ÖÖΣÏóÈçºÎ´¦Àí? ËÄ¡¢ºÎνÄÔĤ´Ì¼¤Ö¢?¾Ù³ö³ýÄÔĤÑ×Ö¢ÒÔÍâµÄÈýÖÖ¼²²¡? Îå.¼òÊöÇÅÄÔСÄÔ½Å×ÛºÏÖ¢ÁÙ´²±íÏÖ?Áù¡¢ºÎν±ÕËø×ÛºÏÖ¢? Æß.ÉÏʧñ¼ÑªË¨Ðγɲ¡Òò¼°ÁÙ´²±íÏÖ? Z5t^D|
F0!Z1S0g
2005ÄêÖÐɽҽ´ó²¡ÉúÊÔÌ⣺ .jJD$FC
Ò»£¬Ãû´Ê½âÊÍ£º e]VW\6J&
1¡£·ÎÐÔÄÔ²¡(Ó¢ÎÄ) Bz/ba *
2¡£·ÇÉÙÄòÐÍARF lTC0kh
3¡£µòÍö(Ó¢ÎÄ) Gwk$<6E
4¡£¹ýÈÈ(Ó¢ÎÄ) C:Jfrg`
¶þ£¬ÎÊ´ðÌâ GL?b!4xx
1¡£ÊÔÊöÓ¦¼¤·´Ó¦Ê±ÏÂÇðÄÔ-´¹Ìå-ÉöÉÏÏÙ¼¤»îµÄÉúÎïѧЧӦ(ÀûÓë±Ö) CHGa_
2¡£Êö¸ÎÐÔÄÔ²¡Ê±°±»ùËáʧºâµÄÔÒòºÍÒýÆð¸Î»èÃԵĻúÖÆ¡£ SnG(/1C8
3¡£ÎªºÎ¸ïÀ¼ÊÏÒõÐÔ¾ú¸ÐȾÒ×ÒýÆðDIC # Wi?I=,
4¡£ÍíÆÚÐÝ¿ËÒýÆðºôÎüË¥½ßµÄ»úÖÆ d.?}>jl
].s;Yxz
ÄÏ·½Ò½¿Æ´óѧ2005ÃâÒßÌâ vv.E6D^x(
1ÒìÊÈÐÔ¿¹Ô Ĥ¹¥»÷¸´ºÏÌå ·Ö×ÓÄ£Äâ ϸ°ûÒò×Ó ¹²´Ì¼¤Òò×Ó Õ³¸½·Ö×Ó Ä£Ê½Ê¶±ðÊÜÌå SmIg HLA Westenbloting r#OPW7mhE
2\ÃâÒßµÄÏÖ´ú¸ÅÄîÊÇʲô£¿ÈçºÎÀí½âËüµÄË«ÖØÐÔ£¿ lqfTF
3.ϸ°ûÒò×ӵĹ²Í¬ÌØÕ÷£¿ÓÐÄÄЩÖ÷ÒªµÄ ÉúÎïѧÌØÕ÷£¿ j
JIP $
4.CD4+ Th1¡¢Th2ÔÚÃâÒßÓ¦´ðÖеÄ×÷Óã¿ v,iZnANZ&P
5.ÃâÒßÄÍÊÜ¡¢ÃâÒßÒÖÖƺÍÃâÒßȱÏݵÄÒìͬµã£¡ 1 !_p
6.¾ö¶¨¿¹ÔÃâÒßÔÐÔµÄÒòËØÓÐÄÄЩ£¿Êµ¼ùÖÐÈçºÎÖƱ¸¸ßЧ¼ÛµÄ¿¹Ì壿 A,F~*LXm
7.¾ÙÀý˵Ã÷È˹¤ÃâÒߵķ½·¨£¬¼òÊöÆäÔÚ¼²²¡·ÀÖÎÖеÄ×÷Óú͵Øλ£¿ Ry>y
8.¿¹¸ÐȾÃâÒßÖУ¬ÌìÈ»ÃâÒßÓë»ñµÃÐÔÃâÒßÊÇÈçºÎÅäºÏ¡¢Ï໥²¹³ä£¿ + ,Krq 3P
`,'/Sdr
2005ÄêкͲ©Ê¿ÃâÒßÊÔÌ⣨רҵ»ù´¡£© Bf*>q*%B{
µÚÒ»²¿·Ö¸÷רҵ¹«¹²ÊÔÌâ Õ¼70·Ö ?#w} S%
1 Åж϶Դí l Xa/5QKC
2 Ìî¿Õ *b
>RUESF
µ¥Á´¿¹ÌåÊÇ£¨ £©ºÍ£¨ £©Á¬½Ó£¬ÊôÓÚ£¨ £©¿¹Ìå 'Ou C[$Z
ÃâÒß¼àÊÓ¹¦ÄܵÍÏÂÒ×·¢Éú£¨ £© %>$<s<y
ÇáÁ´·ÖΪ£¨ £©£¨ £©ÐÍ >eA@s}
_8
²úÉúͬÖÖÐÍ¿¹ÌåÓ㨠£©¶¯ÎïÃâÒß n
h4G;qdU
¿¹Ìå¶àÑùÐԵIJúÉúÔÒò£¨ £©£¨ £©£¨ £© P7F"#R0QB
ÃâÒßÓ¦´ðµÄ²úÉú½×¶Î£¨ £©£¨ £©£¨ £© WGz)-IB!PE
3 Ñ¡Ôñ +51heuu[o
4 Ãû´Ê½âÊÍ10·Ö 4`i8m
LAK £¬ Ö×ÁöÏà¹Ø¿¹Ô£¬TCR£¬ÁöÃ磬J chain¡£ t~(jA9n
5 ¼ò´ðÌâ8·Ö ZGZNZ}~#
²¹ÌåµÄÉúÎïѧ»îÐÔ nsI+04[F
k7iko{5D
µÚ¶þ²¿·ÖΪ¸÷¸öרҵµÄÊÔÌâ30·Ö k4iiL<|
Éö²¡×¨Òµ±Ø´ðÌâ G$f%]A1
1 ÂýÐÔÒÆÖ²ÅųâµÄ¸ÅÄӰÏìÒòËØ£¬·ÀÖη½·¨15·Ö u79- B-YW^
2 ÀÇ´¯ÉöÑ׵ķ¢²¡»úÀí15·Ö jh o
A6I
$Wj= V
·çʪ²¡×¨Òµ±Ø´ðÌâ x.-d)]a!
1ÊɾúÌ忹Ìå¿âµÄ¹¹½¨ *#YZm>h
2 ÃâÒßÇòµ°°×¹¦ÄÜÇøµÄ×÷Óà ~Fuq{e9`
3 ÍüÁË 5Rl\& G\
Sy VGm@
¸¾¿Æ±Ø´ðÌâ eMRH*MyD
ճĤÃâÒßϵͳ U|3!ixk>>w
83c2y;|8
2005Äêͬ¼Ã²©Ê¿ÈëѧÕï¶ÏÌâ g$s;;V/8e
Ò» Ãû´Ê½âÊÍ£¨3`X 5£© ;Xt<\^e
1. PCR i"G'#
n~e
2. Urin Osmol Oin9lg-jR
3. Velcro†ªÒô Zkd{EMW
4. S2¹Ì¶¨·ÖÁÑÒô elR'e6Q
5. Standard bicarbonate y`va6 %u{
S-Y{Vi"2
¶þ ÎÊ´ðÌâ ~W21%T+
1. ²»Í¬Çé¿öϸ¹±Ú¾²ÂöÇúÕŵķ½Ïò¼°±æ±ð¸¹±Ú¾²ÂöÇúÕÅÀ´Ô´µÄ·½·¨¡£ -US:a8`
2. ÊæÕÅÆÚ±¼ÂíÂɵÄÌýÕïÌص㼰ÆäÓëÉúÀíÐÔµÚÈýÐÄÒôµÄÇø±ð¡£ kumV|$Y?kA
3. ¼±ÐÔÇ°±ÚÐĹ£ÐĵçͼµÄÑݱä¹ý³Ì¼°ÌØÕ÷¡£ Q~]oN
4. ²¡Àí·´ÉäµÄ¸ÅÄî¼°ÄÚÈÝ¡£ 7z$Z=cs
5. LDLÖÂASµÄ»úÖÆ¡£ tA#$q;S
6. Å®£¬30Ë꣬·¢ÈÈ¿ÈËÔ¡¢¹Ø½ÚÍ´Ò»¸öÔ¡£Ìå¼ì£º38¶È£¬Ë«Ã沿µûÐκìɫƤÕ˫·ÎºôÎüÒô¼õÈõ£¬ÐØƬʾ˫²àÐØÇ»»ýÒº£¬ÄòPro +++,¹ÜÐÍÄò¡£ 2?~nA2+vm
1£©×î¿ÉÄܵÄÕï¶Ï 'oIE:#b
2£©ÎªÃ÷È·Õï¶ÏÊ×ѡʵÑéÊÒ¼ì²é iI<c
3£©¼ÙÉèÕï¶Ï³ÉÁ¢£¬¶ÔÕï¶Ï×î¾ß¼ÛÖµµÄʵÑéÊÒ½á¹û¡£ t,9+G<)>H
7. ÄУ¬27Ë꣬ÑáÓÍ°é·¦Á¦£¬ÄɲƤ·ô»ÆȾһÖÜ£¬°éºÚ±ãÄòÉÙ£¬ÒâʶÕÏ°Á½Ìì¡£²éÌ壺ÉñÖ¾²»Ç壬Ƥ·ô¹®Ä¤»ÆȾ£¬È«ÉíÉ¢ÔÚðö°ß£¬Íܸ¹£¬³¦ÃùÒô¼õÈõ¡£ *5PQ>d
G
1£©×î¿ÉÄܵÄÕï¶Ï 3wv@wqx
2£©´ËʱÊ×Ñ¡½øÐиÎÔà´¥ÕïµÄ·½·¨¼°¼ì²é½á¹û q8$t4_pF
3£©×îӦѡÔñµÄ¸Î¹¦Äܼì²éÏîÄ¿¡£ z}Cjk6z @
8. ÄУ¬60Ë꣬·´¸´¿ÈËÔ¿È̵´Æø20Ä꣬ÔÙ·¢Á½ÖÜסԺÖÎÁÆ£¬¾¿¹¸ÐȾ¡¢½â¾·¡¢Æ½´ÖÎÁÆÓÐËù»º½â£¬×òÍíÍ»·¢ÐØÃÆ£¬ºôÎüÀ§ÄÑ¡£Ìå¼ì£º¶Ë×ø룬¿Ú´½·¢ç¤¡£Çë·ÖÎö lBfthLBa
1£©¸Ã²¡ÈË×îÓпÉÄܵÄÕï¶Ï
z[f]mU
2£©È·ÕïËùÐèµÄÊ×Ñ¡¼ì²é ZhY{,sy?QO
3£©¼ÙÉè¸ÃÕï¶Ï³ÉÁ¢£¬Æä×î¾ßÕï¶Ï¼ÛÖµµÄÑôÐÔÌåÕ÷¡£ 7
{92_xRL
:=hL}(~]
2005É϶þÒ½²©Ê¿·Ö×ÓÉúÎïѧ£¨×¨Òµ»ù´¡£© iTinZ!Ut
ÈýÁ´DNA ^(TCUY~f&
ת»ùÒò¶¯Îï wG)e8,#
IP3 %d+Fq=<
Ãû´Ê½âÊÍ =wX;OK|U(^
±í´ïÐòÁбêÇ© 'f{13-#X@
»îÐÔëÄ {LiJ=Ebt
Äæת¼ø (n k g
ÖÎÁÆÐÔ¿Ë¡ sR/Yv
¶ËÁ£Ã¸ `e ZDG
ÔÓ½»×èÖÍ·Òë 1T#-1n%[k(
run off transcription OFr"RGW"
µòÍöµ°°× V30w`\1A
ÎÊ´ð ;[ QIHA!
DNA¸´ÖƵĹý³Ì s#5#WNzP
ºËµ°°×ÌåÔÚµ°°×ºÏ³É×÷ÓÃ
|WaWmp(pQ
Äý½º¹ýÂ˲ãÎöµÄÓ¦ÓýøÕ¹ gR!hN.I
6|p8_[
e`
2005ÄêÉ϶þÒ½²©Ê¿Éú»¯¿¼Ìâ P6%qNR/ x
Ãû´Ê½âÊÍ nP*DZC0kE&
Ѫ½¬¹¦ÄÜø IsT}T}p,t
Gµ°°× r } Wdj
·Ö×Ó°é Jhj ]`$J
LCAT t
~qSiHw
¼ò´ð JQ
?8yl
¸ÎÔàËðÉË·²µÇ°×Ë«ÑôÐÔ»úÖÆ jA^yUd-
ÎÊ´ðÌâ ,8DC9yM,
»ùÒòÕï¶ÏµÄ·½·¨£¬¾ÙÀý LntRLB'
ѪNH3µÄÀ´Ô´È¥Â· ,r3`u2)
TRNA¶þ¼¶½á¹¹Ìصã×÷Óà A]iT
uu5 p
ΪʲôÌÇÉãÈ¡¹ý¶à»á·ÊÅÖ 0Bgj.?l
ÐźŴ«µ¼Í¨Â· %d:cC:`
6Á×ËáÆÏÌÑÌÇ£¬¼ºÌǼ¤Ã¸£¬±ûͪËáÔÚÎïÖÊ´úлΪÊàŦµØλµÄÔÒò &iD&C>;pf
DNA±àÂëÐòÁÐÒ»¸öbpµÄÍ»±äÓÐʲôºó¹û£¿¾ÙÀý˵Ã÷ :
HU|BJ>
"$5cKbJ
ÄÏ·½Ò½¿Æ´óѧ2005ϸ°ûÉúβ©ÊÔÌâ r+Sv(KS4i^
1.ÊÜÌå½éµ¼µÄÄÚÍÌ×÷ÓõĹý³ÌÒÔ¼°Ìص㣿 D|Tz{DRG
2.ϸ°û¼äÓм¸ÖÖÁ¬½Ó·½Ê½£¬ÆäÖÐÄÇÖÖ¾ßÓÐϸ°ûͨѶ×÷Óã¬ÒÔ¼°ÎªÊ²Ã´£¿ b!-=L&V
3.³ÉÊì´Ù½øÒò×ÓµÄ×é³ÉÒÔ¼°ÔÚϸ°ûÖÜÆÚµ÷¿ØÖеÄ×÷Óã¿ v#9
i|
4.ϸ°ûÖÜÆÚµ÷¿ØµÄÑо¿·½·¨£¿
9Pvv6WyKy
5.ÔÚ·Ö×ÓºÍϸ°ûˮƽÉ϶Ôϸ°ûË¥ÀϸÅÄî½øÐвûÊö£¿ n2o)K;wW+
ÔºËÉúÎïDNA¾ÛºÏø3ºÍRNA¾ÛºÏøµÄÌصã 8fQfu'LyjY
) F -8
2005Ä긴µ©´óѧ·ÅÁÆ¿¼²©ÊÔÌâ ~"bBwPI
·ÅÉäÖÎÁÆѧ(רҵ¿Î) |pknaz
1. ÏÖ´úÖ×Áö·ÅÉäÖÎÁÆÁ÷³Ì <QgpePyoN
2. ÈçºÎ±£Ö¤°ÐÇø¹´»µÄÒ»ÖÂÐÔºÍ׼ȷÐÔ !F?j'[s8]
3.ºí°©·ÖÐͺÍÖÎÁÆÔÔò +i /4G.=*
4. Ìá¸ß·ÇСϸ°û·Î°©ÁÆЧµÄ·ÅÉäÖÎÁƼ¼Êõ A]%*ye"NT
5. ×ÛºÏÖÎÁƵÄÖØÒªÐÔ Q4Wz5n1yp7
Ö×Áöѧ(רҵ»ù´¡) 6%9 kc+
9
1.Ãû´Ê½âÊÍ g^:`h
VV
ÓÀÉú»¯ µ¥ºËÜÕËá¶à̬ÐÔ ½»½çÐÔÖ×Áö ²»µäÐÍÔöÉú Qo]qs+
2. ÂÛÊöÌâ B}zBbB
2.1 ϸ°û¶ñ±ä !gsrPM
2.2 ¶à»ùÒòÒÅ´«²¡Ìصã L;Y
n q<x
2.3 ÒÖ°©»ùÒò¸ÅÄîºÍÒÖ°©»úÖÆ o=zl{tZV
2.4 ΢תÒƸÅÄîºÍÁÙ´²ÒâÒå FBrh!vQ<
2.5 µòÍöÆÕ±éÉúÎïѧÒâÒå m
WP&N#vwh
P=P']\`p+
2001ͬ¼ÃÒ½¿ÆÔºÉñ¾½âÆÊѧÊÔÌâ Rw63{b/
%<|<%~l&
Ò»Ãû½â£º1´óÄÔ¶¯Âö»· 2Ö²ÎïÉñ¾ÏµÍ³ 3 internal capsule 4 choroid plexus H:Q4!<
;i [;%
¶þÎÊ´ð£º1¡£´©¾º£Ãàñ¼µÄÄÔÉñ¾ÓÐÄÄЩ£¿·Ö±ð¼òÊöËüÃǵķֲ¼ [tC=P&<
A*|\E:fo
2¡£¼¹ËèÄÚ±¡Êø£¬Ð¨Êø£¬¼¹ËèÇðÄÔ²àÊøºÍƤÖʼ¹ËèÊøµÄλÖã¬ÆðÖ¹ºÍ¹¦ÄÜ iTT7<x
*6}'bdQbNP
3¡£ÄÔÉñ¾£¨Â²¿£©µÄ¸±½»¸ÐÉñ¾½ÚÓÐÄÄЩ£¿Æä½ÚÇ°ÏËά·Ö±ðÆð×Ժ䦣¿½ÚºóÏËά·Ö²¼µ½ÄÄÀï¡£ -) +B!"1
t3v_
o4`&
4ij»¼ÕßÍ·²¿ÓÒ²àò¨ÇøÊÜËðÉ˺óÁ½Ð¡Ê±×óÓÒ£¬Í»È»»èµ¹£¬ËÍÒ½Ôº¼ì²é·¢ÏÖ£º£¨1£©ÓÒÍ«¿×É¢´ó£¬Ö±½ÓºÍ¼ä½Ó¶Ô¹â·´ÉäÏûʧ£¬ÓÒÑÛíúÏ´¹£»£¨2£©×óÉÏ£¬ÏÂÖ«²»Äܻ£»£¨3£©×óÏ¥·´É俺½ø£¬×ãèÏ·´ÉäÑôÐÔ¡£Õï¶ÏΪӲĤÍâѪÖײ¢·¢Ð¡ÄÔÄ»ÁÑ¿×ðÞ¡£ÊÔ·ÖÎö£º£¨1£©ËðÉËÁËʲôѪ¹Ü£¿¸ÃѪ¹ÜÆðÓں䦣¿¾ºÎ´¦È룿£¨2£©ÖðÒ»½âÊͳöÏÖÉÏÊö3×éÖ¢×´£¬ÌåÕ÷µÄÔÒò¡£ mYk~ ]a-
fC}uIci
2000 [_KOU2
^%\MOjSN
Ò»Ãû½â &-My[t
1ÄÔÆÁÕÏ 2׶ÌåÍâϵ 3 Ö²ÎïÉñ¾Ïµ 4ÄÚÄÒ yYTO
p^
<|E*aR|M
¶þÎÊ´ð zG%'Cw)8
1¡£ ëè¹Ç¾±¹ÇÕÛÒ×ËðÉËÄÄÌõÉñ¾£¬³öÏÖÄÄЩ֢״£¬ÌåÕ÷£¬ÎªÊ²Ã´£¿ O sy_C<O
Da)_O JYE
2¡£¼òÊöÄԵĶ¯ÂöÀ´Ô´¼°¹©Ñª·¶Î§ tHM0]Gb}
On[yL$?
3¡£Ð¡ÄÔÄ»Çм£ðÞÓëÕí¹Ç´ó¿×ð޵ĽâÆÊѪ»ù´¡£¬»á²úÉúÄÄЩºó¹û p%#'`*<a_
4~;M\h
4¡£ÊÔÊöƤÖʺËÊø l&Y'5k_R
IF6-VFY:6
1999 ^oE#;
aS
iMV=R2t 2
Ò»Ãû½â }YM[aq?6
1ÎÆ×´Ìå 2°×½»Í¨Ö§ 3 ÏËάÊø 4¶¥¸ÇÇ°Çø <29K!
[
|GP&!]
¶þÎÊ´ð tCwB7c-
1¡£ÊÔÊöÐØÉñ¾Ç°Ö§µÄ½Ú¶ÎÐÔºËÖصþÐÔ 'C>sYSL
}iUpBn
2¡£ÄÚÄÒËðÉËʱΪʲô»á³öÏÖ¡°ÈýÆ«×ÛºÏÕ÷¡±£¿ ID{XZ
H_aG\
3¡£ÊÔÊö×µ£»ùµ×¶¯Âöµ×Ðг̣¬·ÖÖ§ºÍ·Ö²¼£¿ cHOC>|
T)ISDK4>S"
4¡£¼¹ËèÐØ7ÓÒ°ìËðÉËʱ»¼Õß»áÓÐÄÄЩ¸Ð¾õ£¬Ô˶¯ÕÏ°£¿¼òÊöÆäÔÒò !?|xeQ}
|TR
+Wn
1998 vF[ 4kDHk
Ò»Ãû½â *{\))Zmhd
1¡£»ùµ×ºË 2¡£´óÄÔ¶¯Âö»· 3 ÄÔÊÒÂöÂç´Ô 4Ç£ÉæÐÔÍ´ 5б·½Ìå # nAq~@X
A<( DYd1H
¶þÎÊ´ð GY^;$ ?
1¡£ÔÚ´óÄÔƤÖÊ»úÄܶ¨Î»ÖУ¬µÚÒ»ÇûÌå¸Ð¾õÇøλÓں䦣¬ÉíÌå¸÷²¿ÔÚ´ËÇøµÄͶӰÓкÎÌصã Ji6.-[:
K5jeazasp
2ÉÏÏÂÔ˶¯Éñ¾ÔªËðÉ˵ÄÖ¢×´ÓëÌåÕ÷Óкβ»Í¬£¬ÎªÊ²Ã´£¿ OEC/'QOae
j"VDqDDz
3Õë´ÌÓÒÊÖСָƤ·ô TH1Éñ¾Ö§ÅäÇøºóÍ´¾õ³å¶¯¾ºÎ;¾¶´«Èë´óÄÔ e,W,NnCICj
Wu8^Z Z{
4ëõÉñ¾µÄ×é³É£¬Ðо¶ºÍ·Ö²¼ Q7tvpU
qOnGP{
5¼¹ËèÇ°½Çϸ°ûµÄÀàÐͼ°Æ书ÄÜ T
Z!@IBu
8lA,3'z
1997 8.+
yZTg
Ò»Ãû½â !+QfQghAT
1¡£Ð¡ÄÔºË 2¡£ÄÔ¸ÉÍø×´½á¹¹ 3 ÖëÍøĤÁ£ 4 ÄÚ²àÇðϵ½»²æ 1-&L-c.
¶þÎÊ´ð }6=)w@v
1¡£ÊÔÊöÉàµÄÉñ¾Ö§Åä¼°Æä×÷Óà ,H^!G\
2¡£´¹ÌåÖ×ÁöѹÆÈÊÓ½»²æºó»¼ÕßµÄÊÓ¾õÓкÎÕÏ°£¬ÎªÊ²Ã´?Çëͬʱд³öÊÓ¾õ´«µ¼¾¶Â· $J&c1
3ëŹÇÍâ¿Æ¾±¹ÇÕÛ£¬ëŹÇÖжιÇÕÛºÍëŹÇÄÚÉÏ÷Á¹ÇÕÛʱ£¬¸÷Ò×ËðÉËÄÇÌõÉñ¾£¬ëŹÇÍâ¿Æ¾±¹ÇÕ۵Ļ¼Õß³£°éÓÐʲô¹¦ÄÜÕÏ° .0~uM!3y
4ÁÙ´²ÉϾ¼¹ËèÖëÍøĤÏÂÇ»´©´Ì³éÈ¡ÄÔ¼¹Òº£¬³£ÔÚ3£4Ñü×µ¼¬Í»¼ä϶´ÌÈ룬Æä½âÆÊѧ»ù´¡ÊÇʲô L'
bY,D(J>
X>P|-n#
1996 g2=PZR$
ÎÊ´ð "^a"`?J
1¡£ÊÔÊö¹ÄË÷µÄÏËά³É·Ö£¬Ðг̷ֲ¼Ó빦ÄÜ e0ot
r_)3F
2£¬ÓÐÄÄЩÉñ¾·Ö²¼ÖÁÊÓÆ÷£¬Çë·Ö±ð¼òÊöËüÃǵÄÐÔÖÊ£¬·Ö²¼ºÍ¹¦ÄÜ i"
)_Xb_1
3¡£Ð¡ÄÔ±âÌÒÌåλÓں䦣¬ÇëÓýâÆÊѧ֪ʶ½âÊÍСÄÔ±âÌÒÌåðÞ·¢ÉúµÄ»úÀíºÍÑÏÖغó¹û K>b4(^lf
4£¬ÊÔÊöµÚËÄÄÔÊÒµÄλÖ㬹¹³ÉºÍ½»Í¨ .`V$j.a
5¡£ëè×ÜÉñ¾ËðÉ˺÷¢Óںβ¿Î»£¬ÊÜËðʧºóÓÐÄÄЩÖ÷Òª±íÏÖ£¬ÎªÊ²Ã´£¿ ?( z"Ub]
6¡£ÄÚÄÒÏ¥²¿Í¨¹ýÄÄЩ´«µ¼Êø£¬ÆäËðÉ˺óÓÐÄÄЩÖ÷Òª±íÏÖ£¬ÎªÊ²Ã´£¿
UT9u?
7¡£ÊÔÊöÄÚÔà´ó£¬Ð¡Éñ¾µÄÆðÔ´£¬ÁªÏµ¼°½ÚºóÏËά·Ö²¼¸Å¿ö #.$y
vLyazVj..
1995 `(=Kp=b
Ò»Ãû½â cO5zg<wF
1¡£±¾Ìå¸Ð¾õ 2¡£Éñ¾ºË 3¡£¹ÌÌåÊø 4¡£ëÝíûÌå qMA-#
¶þ¡£ÎÊ´ð ~id:Rh>o
1¡£ÔÚÄԸɸ½×ÅÓм¸¶ÔÄÔÉñ¾£¬ËüÃǸ÷ÊôºÎÐÔÖÊ£¬¸÷º¬¼¸ÖÖÏËά³É·Ö£¬²¢·Ö±ðд³öËüÃǵÄÆðʼºË»òÖÐÖ¹ºË Z@f{f:Jc/"
2¡£ÈÝÒ׺ϲ¢èãÉñ¾ËðÉ˵ÄëŹǹÇÕÛ³£·¢ÉúÔÚʲô²¿Î»£¬¸ÃÉñ¾ËðÉ˺óÓкÎÔ˶¯Óë¸Ð¾õÕÏ°£¬ÎªÊ²Ã´ VuH ->
3¡£½»¸ÐÉñ¾Ó븱½»¸ÐÉñ¾µÄÖ÷ÒªÇø±ðÔÚÄÄÀï slUi)@b
4ÓҲදÑÛÉñ¾ÊÜËðÉËʱ£¬ÓÒÑÛÍ«¿×Ö±½Ó¶Ô¹â·´ÉäÓë¼ä½Ó¶Ô¹â·´ÉäµÄ±íÏÖÈçºÎ£¬ÎªÊ²Ã´£¬Ç뽫¸Ã·´É侶·һһÁгö ( }Bb=
~
rjO{B`sV*
1994 ( N};.DB1Y
'%XYJ
r:H[
Ò»Ãû½â x&0kIF'lq
1¡£Ç£ÉæÐÔÍ´ 2¡£×¶ÌåÍâϵ 3ÄÔÆÁÕÏ #jW=K&;
{uoF5|O6K
¶þÎÊ´ð #Lp}j?Y
1¡£ÄÄЩÄÔÉñ¾Öк¬Óи±½»¸ÐÉñ¾ÏËά£¬·Ö±ðд³öËüÃǵĽÚÇ°Éñ¾ÔªÃû³ÆºÍλÖÃÒÔ¼°½ÚºóÏËάµÄ·Ö²¼ 1gbFl/i6T
v^8sL` F
2¡£ÔÚ´óÄÔƤÖÊ»úÄܶ¨Î»ÖУ¬µÚÒ»ÇûÌåÔ˶¯ÇøλÓں䦣¬ÉíÌå¸÷²¿ÔÚ´ËÇøµÄͶӰÓкÎÌصã EG\;l9T
$D#h, `
3¡£ÒÀ¾ÝСÄԵĽø»¯¹ý³Ì£¬Ð¡ÄÔ¿É·Ö¼¸²¿£¬¸÷²¿µÄ·¶Î§ºÍ¹¦ÄÜÈçºÎ ,m5i(WL
UU MB"3e
4¡£¾±´ÔµÄ×é³É£¬Î»Ö㬷ֲ¼¼°¸÷Ö÷ҪƤ֧µÄÃû³ÆºÍdz³ö²¿Î» Zis,%XY
hpb|| V
5¡£×ÛÊöÄÔµÄѪҺ¹©Ó¦£¬°üÀ¨Ö÷Òª·ÖÖ§µÄ·Ö²¼ºÍ´óÄÔ¶¯Âö»· }&e HU
tZz%x?3G
1993 H@?} !@
o,dp{+({
Ò»Ãû½â jqc}mI\#
1£¬´óÄÔ¶¯Âö»· 2¡£·´É仡 3¡£ÎÆ×´Ìå 4¡£Ð¡ÄÔÈý¶Ô½Ç 5¡£ÄÚÄÒ \&;y:4&l8
A@)Q-V8*9s
¶þ¡£ÎÊ´ðÌâ KGg
S"d
#?>)5C\Hqy
1£¬ÄÔ¼¹ÒºµÄ²úÉúºÍÑ»· L'?aoRj
:VZS7$5
2¡£×ó²àƤÖʺËÊøÊÜËðËùÒýÆðµÄÃ漡̱»¾ÓëÓÒ²àÃæÉñ¾ÖÜΧÐÔËðÉËËùÒýÆðµÄÃ漡̱»¾ÓÐÎÞÇø±ð£¬ÎªÊ²Ã´£¿ 1J"I.
tJrGRlB>
3Í«¿×¶Ô¹â·´ÉäµÄ;¾¶ o&Xp%}TI
w.(W G+
4ÊÖµÄÉñ¾Ö§Åä EHm
*~Sd
L,y
q=%h|
2001Äê ocZ}RI#Q
1. ÄÔÉñ¾III¡¢VII¡¢IX¡¢XµÄÆðºË¡¢Öպˡ¢ÏËά³É·Ö¡¢Éñ¾Ðг̡¢·ÖÖ§·Ö²¼¼°¹¦ÄÜ¡£ ofQs
/
2. ׶ÌåϵµÄ´«Í³¸ÅÄî¼°ÐÞÕý¡£ WX?nq'nr
3. ¹¹³É׶ÌåÍâϵµÄÖ÷Òª½á¹¹¡¢Éñ¾Í¨Â·ºÍ¹¦ÄܸÅÄî¡£ s_IFl5D]
4. º£Âí½á¹¹µÄϸ°û¹¹Öþ£¬Ö÷ÒªÏËάÁªÏµºÍ±ßԵϵͳµÄ¹¦ÄÜ¡£ 9=MNuV
9/s
5. 5-HTÄÜÉñ¾ÔªÔÚÄÔÄڵķֲ¼¡¢Éñ¾Í¨Â·¡¢Ö÷ÒªÊÜÌå·ÖÐͺͶàÖÖÉñ¾¹¦ÄÜ¡£ bXF8V
6. ¶à°Í°·ÄÜÉñ¾ÔªÔÚÄÔÄڵķֲ¼¡¢Éñ¾Í¨Â·¡¢ÊÜÌå·ÖÐͺ͹¦ÄÜ¡£ K}re{y
}
u;{38~
Ò»¡¢ Ãû´Ê½âÊÍ B]G2P`sN
1¡¢ BaylissЧӦ2¡¢WernickÄÔ²¡3¡¢WernickʧÓï4¡¢Tolosa-Hunt×ÛºÏÕ÷5¡¢Collet-Sicard×ÛºÏÕ÷ GEc-<`-
¶þ¡¢ Ìî¿Õ v9:J 55x
1¡¢ ×é³ÉѪ¹Ü×èÁ¦µÄÒòËØÓÐ_¡¢_¡¢_¡¢¼°__µÈ¡£ B+Qf?1f
2¡¢ µ÷½ÚС¶¯ÂöÕÅÁ¦µÄÒòËØÓÐ_¡¢_¡¢_¼°_µÈ¡£ }'eef"DJ9
Èý¡¢ Ñ¡ÔñÌâ ,5;M(ft#
1¡¢ Ò»ÀýÄÐÐÔ20Ë꣬²éÌå·¢ÏÖÓÒ²à½ÇĤ·´ÉäÁéÃô£¬¼ä½Ó·´ÉäÏûʧ£¬²¡±äÔÚ p7Wt(A
AÓÒ²àÈý²æÉñ¾BÓҲදÑÛÉñ¾C×ó²à¶¯ÑÛÉñ¾D×ó²àÈý²æÉñ¾E×ó²àÃæÉñ¾ n!/0yR2S
2¡¢ Ò»ÀýÄÐÐÔ31Ë꣬1¸öÔÂÀ´×ó²àÉÏ¡¢ÏÂÖ«Âéľ£¬²éÌå·¢ÏÖÓÒ²àÃ沿¼°×ó²àÉÏ¡¢ÏÂÖ«Í´¾õ¼õÍË£¬²¡±ä×î¿ÉÄÜÔÚ pS+w4gW
Aºó¸ù Bºó½Ç CÄÔ¸É DÇðÄÔ EÄÚÊø IdAh)#)
7
3¡¢ Ò»ÀýÄÐ32Ë꣬¾×ÍáÀ´ÕӡÏó×ó²àÃæÉñ¾Ñ×£¬ÏÂÁÐÄĵãÕýÈ· >=; -:
A×ó½ÇĤ·´ÉäÏûʧBÓÒÑÛíú±ÕºÏ²»È«CÕÅ¿ÚÏÂò¢Æ«Ïò½¡²àD×ó²àÃ沿¸Ð¾õÏûʧE×óÑÛíú±ÕºÏ²»È« }? / Blr
4¡¢ Ò»ÀýÅ®ÐÔ50Ë꣬˫ÑÛÊÓÁ¦Ä£ºý£¬²éË«ÑÛò¨²àÆ«Òô£¬Æ䲡±ä²¿Î»ÔÚ 7gf(5p5ZV
AÊÓÉñ¾ Bò¨Ò¶ C¶¥Ò¶ DÊÓÉñ¾½»²æ²¿ EÍâ²àÏ¥×´Ìå % akW43cE
5¡¢ Ò»ÀýÅ®ÐÔ35Ë꣬×óÑÛ±Õ²»½ô£¬×ó¿Ú½ÇÁ÷ÏÑ£¬×î²»¿ÉÄܵÄÖ¢×´ÊÇ ;O`f+rG~
A×óÑÛÁ÷ÀáB×óÀáÒº·ÖÃÚ¼õÉÙC×ó²àζ¾õ¼õÍËD×ó²àÌýÉùÒô¹ýÏìEÑÀ³Ý¿Ú½Ç×óÆ« -\f7qRW^U
6¡¢ Ò»Àý62ËêÈË£¬Í»È»ÓÒ²àÍ·Í´£¬°éŻͣ¬BP:26/18KP£¨195/135mmHg£©ÏÂÁÐÄĸö×î²»¿ÉÄÜ V*\hGNV
A¶îÒ²³öѪBÄÚÄÒ³öѪCÇðÄÔ³öѪDÄÔѪ˨ÐγÉE¶¹×´ºË³öѪ 3 k/E$wOj
7¡¢ Ò»ÀýÄÐ68Ë꣬ÕïΪ׵»ùµ×¶¯Âö¹©Ñª²»×㣬ÏÂÁÐÄÄÒ»ÖÖÊôÓڴ˲¡Ö¢×´ i&>^"_4rc
AÑ£ÔÎBÑÛÇòÔ˶¯ÕÏ°C½»²æÐÔÆ«DÍÌÑÊÕÏ°EʧÓïÖ¢ t/Io.d
8¡¢ Ò»Àý33ËêÅ®ÐÔ£¬¸Ðð·¢ÉÕ5Ì죬²¡ºó³öÏÖË«ÏÂÖ«ÎÞÁ¦²¢Öð½¥¼ÓÖØ£¬Æø¶Ì¡¢ÅÅÄòÀ§ÄÑ£¬²¡ºó8ÌìÀ´Õ×îÖØÒªµÄ²¡ÀíÌåÕ÷ÊÇ£º lg-_[!4Z
AË«ÏÂÖ«¼¡Á¦Ë«ÏÂÖ«¼¡Á¦I BË«Ï¥·´É俺½øCºá¹ßÐԸоõÕÏ°DË«ÏÂÖ«²¡Àí·´ÉäÑôÐÔEÄòäóÁô 1(BLdP3&
9¡¢ ͬÉÏÌ⣬×îÖØÒªµÄ¸¨Öú¼ì²éÊÇ ,:(s=JN+
AÐØ×µÏñ£¨XƬ£©BÄÔ¼¹Òº¼ì²é CÐØ×µCT D¼¡µçͼ EѪÇåÃâÒßÇòµ°°×¼ì²é N E9,kWI
10¡¢ ͬÉÏÌ⣬ÄÔ¼¹ÒºÑ¹Á¦Õý³££¬°×ϸ°û20¸ö£¬µ°°×80mg%£¬ÈçºÎ´¦Àí hE(R[hc
A¾²µÎµØÈûÃ×ËÉB¼¹×µMRI C¾²µÎ¸Ê¶´¼D¾²µÎÉñ¾ÓªÑø¼ÁE¾²µÎ»·±ûɳÐÇ pmB
{b
ËÄ¡¢ ¼ò´ðÌâ #E!^oZm<Z
1¡¢ ¶«·½È˶෢ÐÔÓ²»¯²¡Àí¸Ä±äÓëÎ÷·½ÈËÇø±ðÊÇʲô£¿ R*:$^v@4
2¡¢ ƤÖÊ¡ªÎÆ×´Ì塪¼¹Ëè±äÐÔÖ÷Òª²¡Àí±ä»¯£¿ NRtH?&7
3¡¢ ÂýÐÔÖ²Îï״̬ÁÙ´²±íÏÖÓÐÄÄЩ£¿ L3Y,z3/
4¡¢ Æ«Í·Í´·¢²¡»úÖÆÊÇʲô£¿ Qa=Y?=Za
5¡¢ È«ÃæÇ¿Ö±-ÕóÂη¢×÷ÖÐðïÐԻ´«²¥¾¶Â·ÊÇʲô£¿ 9{;L7`<
Îå¡¢ ÎÊ´ðÌâ I9qZE
=i
1¡¢ Alzheimer²¡Ö÷Òª²¡Àí¸Ä±äÊÇʲô? Q ")Xg:
2¡¢ ÊÔÊöÖØÖ¢¼¡ÎÞÁ¦µÄ·¢²¡»úÖÆ£¿ >ZOlSLu
3¡¢ Õð²üÂé±ÔÉú»¯¸Ä±äÊÇʲô£¿ $XQg
at@&]
@)h>vg
> 2004ÄêÊ×Ò½Éñ¾½âÆÊÌâ %9>w|%+;U+
> Ò»¡¢ Ãû´Ê½âÊÍ£¨Ã¿Ìâ5·Ö£¬¹²60·Ö£© (o|bst][S
> 1¡¢ Ñü÷¾¸É2¡¢½Þ×´Éñ¾½Ú3¡¢¼¹Ëè½Ú¶Î4¡¢çÖºË5¡¢±ßԵϵͳ6¡¢Ç°ÄÔÄÚ²àÊø7.saphenous nerve 8.celiac plexus 9.climbing fiber 10.primary somatic motor area 11.cavernous sinus 9Q,>I6`l
> 12. tympanic nerve P'8RaO&d
> ¶þ¡¢Ñ¡ÔñÌ⣨2*15£¬1-7Ϊµ¥Ñ¡£¬8-15Ϊ¶àÑ¡£© es6YxMg
> 1¡¢ Ö§ÅäµÚ¶þò¾×´¼¡µÄÉñ¾ÊÇ D?_K5a&v,
> A ¼¡Æ¤Éñ¾BÒ¸Éñ¾CÕýÖÐÉñ¾D³ßÉñ¾EèãÉñ¾ (y]Z *p:EW
> 2¡¢ Ö§ÅäÈùÏÙ·ÖÃڻµÄÉñ¾ÊÇ o+.L@3RT4
> AÃæÉñ¾BÈý²æÉñ¾CÃÔ×ßÉñ¾DÉàÑÊÉñ¾E¸±Éñ¾ ,7@\e&/&
> 3¡¢ ´óÄÔ´ó¾²Âö×¢ÈëµÄ½á¹¹ÊÇ }BC%(ZH6
AÉÏʸ״ñ¼BÏÂʸ״ñ¼Cº£Ãàñ¼DÖ±ñ¼Eñ¼»ã H};1>G4
> 4¡¢ ÒâʶÐÔÇû¸É¡¢ËÄÖ«Éî¸Ð¾õ´«µ¼Â³µÄ½»²æ²¿Î»ÊÇ 9~W]D!m,
A¼¹ËèBÑÓËèCÄÔÇÅDÖÐÄÔE±³²àÇðÄÔ ;:bp?(
> 5¡¢ ÄÚÔà´óÉñ¾½»»»Éñ¾ÔªµÄλÖÃÊÇ ~o_JZ:
A×µÅÔÉñ¾½ÚB׵ǰÉñ¾½ÚCÆ÷¹ÙÅÔÉñ¾½ÚDÆ÷¹ÙÄÚÉñ¾½ÚE¼¹Éñ¾½Ú 4ekwmw(ox
> 6¡¢ ÓëºÚÖÊÓÐÍù·µÏËάÁªÏµµÄ½á¹¹ÊÇ ,1~zYL?
AÐÂÎÆ×´ÌåB¾ÉÎÅ×´ÌåCÐÓÈÊÌåDÈéÍ·ÌåEÄÚ²àÏ¥×´Ìå kfnh1|D=aY
> 7¡¢ »¼Õß²»ÄÜÓÃÉìλµÄʳָÓëÖÐÖ¸¼ÐסֽƬ£¬ÊÜËðÉ˵ÄÉñ¾ÊÇ Q$5t~*$`
AèãÉñ¾ÉîÖ§BèãÉñ¾Ç³Ö§C³ßÉñ¾ÉîÖ§D³ßÉñ¾Ç³Ö§EÕýÖÐÉñ¾·µÖ§ m'}`+#C%)
> 8¡¢ ÓÐÃÔ×ßÉñ¾²ÎÓëµÄÉñ¾´ÓÓÐ H14Q-2U1xa
A¾±ÄÚ¶¯Âö´ÔBʳ¹Ü´ÔC·Î´ÔD¸¹Ç»´ÔEÅè´Ô m,\+RUW'
> 9¡¢ Òɺ˷¢³öµÄÏËά¼ÓÈëµÄÉñ¾ÓÐAÉàÑÊÉñ¾BÃÔ×ßÉñ¾C¸±Éñ¾DÃæÉñ¾EÉàÏÂÉñ¾ s\ C ,5
> 10¡¢ ÓëÉñ¾ÄÚ·ÖÃÚÓйصĺËÓÐAÊÓÉϺËBÈéÍ·ÌåºËCÊÒÅÔºËD©¶·ºËEÊÓ½»²æÉÏºË "yQBHYP
> 11¡¢ ²ÎÓë×é³ÉСÄÔϽŵÄÏËάÊøÓÐA¼¹ËèСÄÔÇ°ÊøB¼¹ËèСÄÔºóÊøCéÏéСÄÔÊøDШСÄÔÊøEǰͥСÄÔÊø 9
3)fC
> 12¡¢ ÊôÓÚÄԸɵÄÍø×´½á¹¹µÄºËÍÅÓÐAШÊøºËBШÐκËCШÊø¸±ºËD±ÛÅÔºËEÖзìºË /lECgu*#69
> 13¡¢ Ð̾¯¼¹ËèÍâ²àË÷ÄÚµÄÏËάÊøÓÐA¼¹ËèСÄÔÇ°ÊøB¼¹ËèСÄÔºóÊøCºìºË¼¹ËèÊøDÇ°Í¥¼¹ËèÊøE¶¥¸Ç¼¹ËèÊø }T$BU>z33N
> 14¡¢ ÊôÓÚ´óÄÔƤÖÊͶÉäÉñ¾ÔªµÄÓÐA׶Ìåϸ°ûB¿ÅÁ£Ï¸°ûCËóÐÎϸ°ûDˮƽϸ°ûE Martinotliϸ°û :7 LA/j
> 15¡¢ ¹ØÓÚÄÚ²à×ÝÊøµÄÕýÈ·ÃèÊöÓÐAÖ÷ÒªÀ´×ÔÇ°Í¥Éñ¾ºËȺBÐÐÓÚ¼¹ËèÇ°Ë÷CÏ´ïÑüËèDÖ¹ÓÚ1-4²ãÖмäÉñ¾ÔªEÍê³ÉÍ·¡¢¾±×ËÊÆ·´ÉäÐÔµ÷½Ú 8:& !F`o
> Èý¡¢12*5=60·Ö HY5R
> 1¡¢ ÊÔÊöÑÛµÄÉñ¾Ö§Å䣿 Zy7kPL;b
> 2¡¢ ÏÂÖ«µÄ±¾Ìå¸Ð¾õÊÇÈçºÎ´«µÝµ½´óÄÔƤÖʵģ¿ AwG0E`SU
> 3¡¢ ÊÔÊöÒÔϽṹÊÇÈçºÎ·Ö²ãµÄ£¿£¨1£©ÅÔÖÐÑëСҶ£¨2£©ÈÞÇò£¨3£©ÏÂÍÐ 4k^P1
> 4¡¢ ¼òÊöУַÊú뼡µÄÉñ¾Ö§Å䣨°üÀ¨Ðо¶£© %WU=Vy 4
> 5¡¢ ÄãÊÇÈçºÎÀí½âÇ£ÉæÐÔÍ´µÄ£¿ 2z
!05]B%
[4#HuO@h
1¡£Ò»¸öÈËÌýµ½ÌáÎÊ£¬ºó»Ø´ðÎÊÌ⣬Çëд³öËù¾¹ýµÄÉñ¾Í¨Â·£¨°´Ë³Ðò£© `0ym3} (O
2¡£ÑÓËåºó¶¯Âö¹£ÈûȱѪ¿ÉÄÜÊÜËðµÄÉñ¾½á¹¹¼°ÆäÁÙ´²±íÏÖ¡£ w98M#GqV
3¡£´ÓÉñ¾·¢Óý½Ç¶È·ÖÎö£¬ÄÔ¸ÉÉñ¾ºËÍŵķֲ¼¹æÂÉ¡£ 9BZ B1oX
¼ò´ðÌ⣺1¡£Í»´¥ 2¡£×¶ÌåÍâϵ ¡¡¡¡¡¡ Ydr
h+
a%c <3'
µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ X% 05[N
ѧ¿Æרҵ£º´«È¾²¡Ñ§ *e [*
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ qZ!kVrmg&
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) #"-_ ~
1. ICAM-1 +PE-j| D
2. interleukin 12(IL-12) 0B8Wf/j?M
3. tumor infiltrating lymphocyte jo&j<3i
4. TCR/CD3 complex Io<T'K
5. hematopoietin receptor family V/xXW=
6. individual idiotype(IdI) qery|0W
7. integrin pmBN?<
8. colony-stimulatory factor (CSF) +)yoQRekX
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© v\bWQs1
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? e+!xy&u@u
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ TI8\qI
W
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠl@SV!keQ
4. ¼òÊö¿¹ÔÌá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ 9j^rFG!n
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) ^|oI^"IQ=
1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔÀí¡£ >k\p%{P
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? L44|/~
HdlOGa6C
<LH6my
;Egl8Vhr
{.oz^~zs]g
"Ia.$,k9
µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ G)YmaHeI;[
LkHH7Pd@
ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ vG6*[c8
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ }U=}5`_]D
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 0x5\{f
1. CD4
TR*vZzoy
2. T cell receptor(TCR) v B~VJKD
3. immunoglobulin superfamily (IgSF) 9ec
?L
4. selectin |g \_xl
5. anti-idiotypic antibody (¦ÁId) G"3KYBN>
6. major histocompatibility complex(MHC) oR`rs[Kj
7. immunotolerance *GYLj[
8. biological reponse modifier(BRM) S=kO9"RB]
9. immune reponse gene (Ir gene) \s)$[pAF
10. reshaped antibody (or reconstituted antibody) s\~j,$Mm2
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 6qmV/DL
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ POc<XLZB
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? ;2`t0#J$]
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ lxZ9y
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? z^*g2J,
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) -#;ZZ\fdj
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ WoNJF6=?
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? [oBRH]9cq
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? *C|*{!
E}%Pwr
¡¡¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺
)bYOy+2g
H/ e jO_{
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? OcpvY~"Pr
{C?$osrr
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? (p'/a.bn
FmF[S&gFRs
¡¡ opn6 C )
q~iEw#0-L
l{?9R.L
h)W#
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ fTX|vy<EMI
"5$p=|
ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ FB,rQ9D
./DlHS;
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ \%}]wf}
/18fpH|
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© DuAix)#FN9
%0vsm+XQ0E
1. CD8 c9nv=?/}f
FW3E UC)P
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) jC>mDnX
[ *C~BM
3. immunoglobulin fold(Ig fold) Y)(w&E>1
}a UQ#x
4. cadherin (Ca-dependent cell adhesion moleculers) 7FaF]G
lFA-T I&
5. idiotype-anti-idiotypic antibody immune network theory I+^iOa
Jfv'M<I
6. HLA class II antigen nemC-4}
DV({! [EP
7. complementarity-determining region (CDR) tk 5p@l
hDoFF8)c
8. perforin(or pore-forming protein ,PFP) 7''iT{-[p
D^t:R?+
9. high affinity IL-2 receptor RA+M.
`6N
cE-oJ
10. artificial active immunization
z-]ND
7a/
BS(kq<
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© d,'gh4C
PCH$)F4^
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠm("KLp8
>B$ IrM7J
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 iK5[P
[ 'B u
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ 1p-<F3;
x'Nc
}
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԡ¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ d7Cs a
c
02:`Joy2D
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) Smh=Q4,W
E;k$ICOXA
1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ *u[@C
B'PS-Jr
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? r. rzU
cwHbm%
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ zf\$T,t)
cw_B^f8^
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ *^Z -4
Pvm pWa
¡¡ kH[thRk}
T#Z#YM k
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ +R8dy
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ + =U9<8
aCfWbJ@qiG
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ SE
M-t
I3ugBLxVC3
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© u3jLe=Y'\
)~w
bu2;
1. immunoglobulin gene rearrangement BGstf4v>A<
|g<l|lqz|
2. the common chain of cytokine receptor (or a cytokine receptor <yw=+hz[u
:vFY
qoCn
subunit shared by some cytokine receptors) @G|z_
\`*]}48Z
3. flow cytometry(FCM) , LqfwA|
@~i :8
4. carrier effect wZj`V_3
Zo Ra^o
5. positive selection of T lymphocytes in thymus 8(!?y[
^jk-GRD*
6. mouse TH1(Th1) and TH2(Th2) subsets <CS,v)4,nH
i06|P I
7. perforin (pore-forming protein ,PFP) ]C-a[
[q|8.>sB
8. ADCC(antibody-dependent cell-mediated cytotoxicity) N1l^%Yf J
NU3s^ 8\(
9. SH-2(src-homology region 2) ~yY5pnJ
{t('`z
10. Ab2¦Â (internal image) 5^N`~
'
p
T8S
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© {YIVi:4q
sQO>1bh
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? u X(
#+
@CA{uP;
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? y# IUDnRJ
1@q"rPE^
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠF^!_!V B
\Bl`;uXb
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ p'=XW#2 >
r3~YGY
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠv2vtkYQN
vZ|Wj] ;o
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) 6I\4Yv$N
U)_x(B3d/
ÃâÒßѧרҵ£º hhJs$c(
KY9@2JG
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ -8sB\E
nO8e'&|
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? N. 0~4H
%U
)fbYP@9>a
´«È¾²¡Ñ§×¨Òµ£º ]KQBek#DD
Bv^5L>JZ/
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 3Sn#
M{wH
Wtp;se@#
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ !eD
f}~
y~py+:_
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ :a)` iJnb
rf
=Wq_
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? l' Uj"9r,
uiaZ@
OsgjSJrf
)8V=!73
uVzvUz{b
U;FJSy
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ jJe?pT]o
m 8P`n
ÃâÒßѧÊÔÌâ :E2 ww`
$u::(s}
x<
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© dEPLkv
6Vu)
1. Fas(CD95)/FasL B[;aNyd<
o|y1 m7X
2. common chain of cytokine receptor 1F{,Zr
__,F_9M
3 . TCR/CD3 complex Eb9n6Fg
Tvd: P^C
4. negaive selection of thymocytes (E7C
9U*
SX[
5. artificial active immune Uh3N#O
.:B;%*
6. anti-idiotypic #:tC^7qk
}hS$F
7. IgSF #F'8vf'r
f;obK~b[
8. Integrin ? w@)3Z=u
P}"uC
`036
9. chemokine 'm.+ S8
!x
EGN@
10. B7/CD28 ?{wD%58^oG
D|IS@gWa
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© Pdk#"H-j
`pfRY!
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ -v$ q8_$m"
1Hs'YzvY
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 +IG=|X
[I}xR(a@n
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ =-/sB>-C
@x_0AkZU
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ hpYW1kfQl
u4ZOHy_O^
$ J!PSF8PL
>{>X.I~
;
KT/;I
6_>(9&g`zV
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ >tm4Rg~y
w|61dB
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© EF'8-*
/ACau<U]t
1. B7/CD28 5 hW#BB
cJzkA^T9
2. Th1 subset DC0ON`
~bz$] o-<
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© uobQ
S!
a
I1tG
4. antibody affinity maturation Tt4Q|"CJA
+3Z+#nGtk
5. AP-1 S2>$S^[U
/z :1nq
6. single chain variable fragment£¨ScFv£© K9+\Z
I8k+Rk*
7. NK cell receptor X6xs@tgQ
Y++n0sK5<
8. Zinkernagel-Doherty phenomenon Nw1Bn~yx<R
X$_pDF&\z
9. Ig fold O+]'*~a
XW~a4If
10. CD40/CD40L #Y'ewu;qJ
D;[%*q*
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© )&l5I4CIf
|XV
`A)=f
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ u#NX`_
fNBI!=
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ POf xN.
g!OcWy)7
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ }KT$J G?
PcI~,e%
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 9FPqd8(]*V
b1QH
ZY\g{
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ (LJ7xoJ^
[Y
j:H
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ P)LOAe1'
oDayfyy4y)
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ cp0yr:~
{ft |*
'p@m`)Z
fIJX5)D
'H#0-V"=
lCTXl5J5
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ Cq'{%
#Nad1C/]
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© 1.TIUH1
Z?V vFEt%
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© z, FPhbFn
C](djkA$
1.Co-stimulators (or co-stimulating molecules) *`LrvE@t
0A-yQzL|
2.NK-kB (!qfd
Qq#
P1Eg%Y6
3.Immunoglobulin superfamily 6']G HDK
Br.UN~q
4.antigen-presenting cell (APC) wG6Oz2(
ydj*Jy'
5.death domain DtJ3`Jd
lY2~{Y|4s
6.CCR and CXCR ] SLeWs
6y57m;JW/
7.Lectin (or mitogen) +5 gX6V\
` N
R,8F
8.Clusters of differentiation, CD) :$gs7<z{rm
N9s.nu
9.B7 family 1ox#hQBoS
>< P<k&
10.Cytotoxic T lymphocyte, CTL) :UAcS^n7h"
k\9kOZW
11.IL-15 and IL-15 receptor (IL-15R) \I^"^'CP
[2>zaag
12.MHC restriction :eT\XtxM~{
D>o u,
13.Affinity-chromatography r!w*y3
Xwjm
T
14.Cyctosprin A, CsA cIC/3g}]
>j*0fb!:]
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 't
cve2Tt
wZ69W$,p
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© A$n.'*gK
%++S;#)~
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 q8.Z7ux
L{l}G,j<
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ >Q
^ mR
"Mv^S'?>
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌص㡣 2"j&_$#l5X
Pgq(yPC
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© dM19;R@4
$}5M`p\&C
ÃâÒßѧרҵ£º n "^rS}Y]
HZS.%+2
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 6 b?K-)kL
*f{4_ts
Ïû»¯ÄÚ¿Æ£º w)1SZ}
sSD&'K=lq
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 7}~nQl2
(^sb('"
ѪҺ²¡Ñ§×¨Òµ£º xaV3N[Zd
3-n&&<
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ s?nj@:4
<Hz11
}<(
p)"EenUK
m7XN6zX
jGJf[:M&Pm
RU=g|TL
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ K@!
hrye
*/TO$ ^s
(רҵ»ù´¡: ÃâÒßѧ) @T.F/Pjhc
KBI1t$
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
:J )^gc
Et}%sdS
1. ADCC(antibody dependent cell-mediated cytotoxicity) 4j i#Q
N "
eK9>
2. »·æß¾úËØ(cyclosporin) NA/Sv"7om
KpS=oFX{}
3. KIR(killer cell inhibitory receptor) y] Cx[
Aqg$q* Y
4. HLDA(human leucocyte differentiation antigen) r.:f.AY{
tEibxE
5. Interleukin 18(IL-18)
TLVfu4
6. ÕûºÏËØ(integrin) pH@yE Vf
7. Fas/FasL +l7Bu} _?
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) m^)\P?M5|
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) (ueH@A"9;
10. Th1/Th2 *t={9h
11. »ùÒòÒßÃç(DNAÒßÃç) YsO`1D
12. chemokines and chemokine receptor v57Kr ,
13. ÃâÒßÄÍÊÜ 6skd>v UU
14. ¹²´Ì¼¤·Ö×Ó `0{qfms
15. ËÀÍö½á¹¹Óò(death domain) mj9]M?]
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) ' 94HVag
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? `X`|]mWj
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠO9{A)b!HB
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î ;{n*F=%uC
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ ,-Lv3
(3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå )9!ZkZbv_m
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ E
6!V0D
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ o`}8ZtD
Ax!fvcsN
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ):Ekf2
ÎÊ´ðÌâ(ÿÌâ25·Ö) 8[8U49V9(
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ U(:t$SBKy
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ I
RI<no
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ =E8Kacu%
4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£ z&[[4[
@jD19=
µÚËľüÒ½´óѧһ¾Å¾Å°ËÄ격ʿѧλÑо¿ÉúÈëѧÊÔÌâ 7|?Ht]
6K9-n}z
·Ö×ÓÉúѧ(2)¡ª¡ª×¨Òµ»ù´¡ lHPhZ(Z
j !`2Z@
-------------------------------------------------------------------------------- V0:db
v8A{q
¡¡ :#W>lq@H
Aj=c,]2
Ò»¡¢½âÊÍÏÂÁÐÃû´Ê£¨Ã¿Ìâ5·Ö£¬¹²40·Ö£© :SpPT
1. µ°°×¼¤Ã¸(protein kinase) >Q^*h}IdW
2. ÔöÇ¿×Ó(enhancer) H0mDs7
3. SH2½á¹¹Óò(SH2 domain) VnMiZAHR
4. ¾ÛºÏøÁ´·´Ó¦(PCR) o/\z4Ri)$
5. »ùÒòÖÎÁÆ(gene therapy) !^A t{[U
6. ±äÐÔµ°°×ÖÊ(denatrued protein) i{ /
nHrN
7. ÐźÅëÄ(signal peptide) (fWQ?6[
8. cDNAÎÄ¿â p&;,$KDA
¶þ¡¢ÎÊ´ðÌâ(Ñ¡´ðËĵÀÌâ,¹²¼Æ60·Ö) w9a6F
1. ʲôÊǵ°°×ÖʵÄÒ»¼¶¡¢¶þ¼¶¡¢Èý¼¶¡¢Ëļ¶½á¹¹£¿ËüÃÇÒÀ¿¿Ê²Ã´ÑùµÄÁ´ºÍÁ¦½¨Á¢ÆðÕâЩ½á¹¹£¿ËüÃÇÖ®¼äµÄ¹ØϵÊÇʲô£¿(15·Ö) %AuS8'Uf
2. ¼òÊöÖØ×éDNA¼¼ÊõµÄ¶¨Òå¡¢ÔÀíºÍÖ÷Òª¹ý³Ì£¬½áºÏÄãµÄרҵ¾Ù³öÒ»¸öÓ¦Óøü¼ÊõµÄʵÀý²¢ËµÃ÷ÆäÒâÒå¡£(15·Ö) k$} 6Qd
3. ¼òÊö°©»ùÒòÓëÒÖ°©»ùÒòµÄ¶¨Òå,¸÷¾ÙÒ»Àý˵Ã÷ÆäÔÚÖ×Áö·¢ÉúÖеÄ×÷Óá£(15·Ö) &rxR"^x\
4. ÒÔÈéÌDzÙ×Ý×Ó(»ò³ÆΪÈéÌDzÙ×ÝÔª)ºÍÉ«°±Ëá²Ù×Ý×ÓΪÀý¼òÊöÔºËϸ°û»ùÒò±í´ïµ÷¿ØÔÀí¡£(15·Ö) "mkTCR^]e
5. ¼òÊöÕæºËϸ°û»ùÒò±í´ïµ÷¿ØµÄ»ù±¾»·½Ú¡¢Ö÷ÒªµÄµ÷¿Ø·Ö×Ӻ͵÷¿Ø·½Ê½¡£(15·Ö) (tP^F)}e5
×¢Ò⣺ÇëÑ¡´ðËĵÀÌ⣬¶à´ðÕß¿ÛÈ¥µÃ·Ö×î¶àµÄ´ðÌ⣡£¡